Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Novel Stem Cell-Targeted Therapy for Multiple Myeloma Based on Dual Inhibition of EZH1/2

Makoto Nakagawa, MD, Shuhei Fujita, MD BS, Daisuke Honma, PhD, Kazushi Araki, D.V.M., PhD, Tatsuya Inoue, Ayako Kato, Koichiro Inaki, PhD, Chisa Wada, Ono Yoshimasa, Yasuharu Nakashima, MDPhD, Issay Kitabayashi, PhD

Blood (2017) 130 (Supplement 1): 590.

https://doi.org/10.1182/blood.V130.Suppl_1.590.590

Published: 2017

Journal Articles

EZH1/2, SWI/SNF, and MLL2 Dependent Heterochromatin Formation and Abnormal Transcriptome in Hematological Malignancies

Makoto Yamagishi, PhD, Dai Fujikawa, PhD, Makoto Hori, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Seiichiro Kobayashi, MD, PhD, Masako Iwanaga, MD PhD MPH, Atae Utsunomiya, MD, Seiji Okada, MD, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD, Kazushi Araki, D.V.M., PhD, Toshiki Watanabe, MD, PhD, Kaoru Uchimaru, MD, PhD

Blood (2017) 130 (Supplement 1): 1200.

https://doi.org/10.1182/blood.V130.Suppl_1.1200.1200

Published: 2017

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results

Dai Maruyama, MD PhD, Kensei Tobinai, MD PhD, Shinichi Makita, MD, PhD, Takashi Ishida, MD PhD, Shigeru Kusumoto, MD, Kenji Ishitsuka, MD PhD, Makoto Yoshimitsu, MD PhD, Yoshitaka Imaizumi, MD PhD, Yasushi Sawayama, MD, PhD, Shogo Takeuchi, MD, Atae Utsunomiya, MD, PhD, Kunihiro Tsukasaki, MD PhD, Sumiaki Fujitani, MSc, Kazushi Araki, D.V.M., PhD

Blood (2017) 130 (Supplement 1): 4070.

https://doi.org/10.1182/blood.V130.Suppl_1.4070.4070

Published: 2017

Journal Articles

Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

Daisuke Honma, PhD, Nobuaki Adachi, PhD, Osamu Kanno, PhD, Jun Watanabe, Makoto Hirasawa, Emi Nosaka, Machiko Shiroishi, Takeshi Takizawa, Isao Yasumatsu, Takao Horiuchi, PhD, Akira Nakao, PhD, Keisuke Suzuki, Tomonori Yamasaki, Katsuyoshi Nakajima, Miho Hayakawa, Takanori Yamazaki, Kazushi Araki, D.V.M., PhD, Kosaku Fujiwara, PhD

Blood (2017) 130 (Supplement 1): 2073.

https://doi.org/10.1182/blood.V130.Suppl_1.2073.2073

Published: 2017

Journal Articles

Development and Molecular Analysis of Synthetic Lethality By Targeting EZH1 and EZH2 in Non-Hodgkin Lymphomas

Makoto Yamagishi, PhD, Makoto Hori, Dai Fujikawa, PhD, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Takeo Ohsugi, D.V.M., PhD, Kazumi Nakano, PhD, Makoto Nakashima, Seiichiro Kobayashi, MD, PhD, Masako Iwanaga, MD, PhD, Atae Utsunomiya, MD, PhD, Seiji Okada, MD, PhD, Kunihiro Tsukasaki, MD, Kensei Tobinai, MD, PhD, Kazushi Araki, D.V.M., PhD, Toshiki Watanabe, MD, PhD, Kaoru Uchimaru, MD PhD

Blood (2016) 128 (22): 462.

https://doi.org/10.1182/blood.V128.22.462.462

Published: 2016

Journal Articles

The Role of IDH Mutants, Which Are Promising Therapeutic Targets for Acute Myeloid Leukemia

Yoko Ogawara, PhD, Hironori Matsunaga, Takahiko Seki, PhD, Yukino Machida, Kazushi Araki, D.V.M., PhD, Issay Kitabayashi, PhD

Blood (2015) 126 (23): 3796.

https://doi.org/10.1182/blood.V126.23.3796.3796

Published: 2015

Journal Articles

Novel Leukemia Stem Cell-Targeted Therapy for Acute Myeloid Leukemia Based on Dual Inhibition of Ezh1/Ezh2

Shuhei Fujita, MD BS, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Kazushi Araki, D.V.M., PhD, Emi Takamatsu, PhD, Kazumasa Aoyama, PhD, Atsushi Iwama, MD PhD, Issay Kitabayashi, PhD

Blood (2015) 126 (23): 457.

https://doi.org/10.1182/blood.V126.23.457.457

Published: 2015

Journal Articles

Polycomb-Dependent Epigenetic Landscape in Adult T Cell Leukemia (ATL); Providing Proof of Concept for Targeting EZH1/2 to Selectively Eliminate the HTLV-1 Infected Population

Makoto Yamagishi, PhD, Dai Fujikawa, Daisuke Honma, PhD, Nobuaki Adachi, PhD, Shota Nakagawa, Makoto Hori, Naoya Kurokawa, Ai Soejima, Kazumi Nakano, PhD, Tadanori Yamochi, PhD, Makoto Nakashima, Seiichiro Kobayashi, MD, PhD, Yuetsu Tanaka, MD, PhD, Masako Iwanaga, MD, PhD, Atae Utsunomiya, MD, PhD, Kaoru Uchimaru, MD, PhD, Kunihiro Tsukasaki, MD, PhD, Kazushi Araki, D.V.M., PhD, Toshiki Watanabe, MD, PhD

Blood (2015) 126 (23): 572.

https://doi.org/10.1182/blood.V126.23.572.572

Published: 2015

NARROW

Novel Stem Cell-Targeted Therapy for Multiple Myeloma Based on Dual Inhibition of EZH1/2

EZH1/2, SWI/SNF, and MLL2 Dependent Heterochromatin Formation and Abnormal Transcriptome in Hematological Malignancies

First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results

Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

Development and Molecular Analysis of Synthetic Lethality By Targeting EZH1 and EZH2 in Non-Hodgkin Lymphomas

The Role of IDH Mutants, Which Are Promising Therapeutic Targets for Acute Myeloid Leukemia

Novel Leukemia Stem Cell-Targeted Therapy for Acute Myeloid Leukemia Based on Dual Inhibition of Ezh1/Ezh2

Polycomb-Dependent Epigenetic Landscape in Adult T Cell Leukemia (ATL); Providing Proof of Concept for Targeting EZH1/2 to Selectively Eliminate the HTLV-1 Infected Population

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only